Emergent Biosolutions Inc (EBS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emergent Biosolutions Inc (EBS) has a cash flow conversion efficiency ratio of 0.149x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($77.70 Million) by net assets ($522.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Emergent Biosolutions Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Emergent Biosolutions Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Emergent Biosolutions Inc (EBS) financial obligations for a breakdown of total debt and financial obligations.
Emergent Biosolutions Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emergent Biosolutions Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RCE Capital Berhad
KLSE:9296
|
0.049x |
|
Orient Electric Limited
NSE:ORIENTELEC
|
-0.059x |
|
Masoval AS
OL:MAS
|
0.042x |
|
TMK
KLSE:5330
|
N/A |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
0.051x |
|
Globe Trade Centre S.A.
WAR:GTC
|
0.027x |
|
Taimide Tech Inc
TW:3645
|
0.071x |
|
Zumiez Inc
NASDAQ:ZUMZ
|
0.018x |
Annual Cash Flow Conversion Efficiency for Emergent Biosolutions Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Emergent Biosolutions Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Emergent Biosolutions Inc (EBS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $522.60 Million | $170.60 Million | 0.326x | +168.50% |
| 2024-12-31 | $482.80 Million | $58.70 Million | 0.122x | +138.27% |
| 2023-12-31 | $649.30 Million | $-206.30 Million | -0.318x | -1188.61% |
| 2022-12-31 | $1.38 Billion | $-34.10 Million | -0.025x | -112.37% |
| 2021-12-31 | $1.61 Billion | $321.10 Million | 0.199x | -46.30% |
| 2020-12-31 | $1.45 Billion | $536.90 Million | 0.371x | +114.83% |
| 2019-12-31 | $1.09 Billion | $188.00 Million | 0.173x | +317.70% |
| 2018-12-31 | $1.01 Billion | $41.80 Million | 0.041x | -81.88% |
| 2017-12-31 | $912.35 Million | $208.14 Million | 0.228x | +154.30% |
| 2016-12-31 | $596.21 Million | $53.49 Million | 0.090x | +33.18% |
| 2015-12-31 | $660.02 Million | $44.46 Million | 0.067x | -66.82% |
| 2014-12-31 | $553.20 Million | $112.32 Million | 0.203x | +2.42% |
| 2013-12-31 | $489.17 Million | $96.97 Million | 0.198x | +121.08% |
| 2012-12-31 | $442.13 Million | $39.64 Million | 0.090x | +156.05% |
| 2011-12-31 | $416.73 Million | $14.59 Million | 0.035x | -86.86% |
| 2010-12-31 | $373.56 Million | $99.54 Million | 0.266x | +112.94% |
| 2009-12-31 | $243.81 Million | $30.51 Million | 0.125x | +240.94% |
| 2008-12-31 | $199.35 Million | $7.32 Million | 0.037x | -88.67% |
| 2007-12-31 | $171.16 Million | $55.45 Million | 0.324x | +1204.61% |
| 2006-12-31 | $138.47 Million | $-4.06 Million | -0.029x | -104.15% |
| 2005-12-31 | $59.74 Million | $42.25 Million | 0.707x | +76.50% |
| 2004-12-31 | $22.95 Million | $9.20 Million | 0.401x | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more